Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to Anticholinergics

Schmid, Daniel; Sauermann, Peter; Werner, Matthias; Schuessler, Bernhard; Blick, Nadja; Muentener, Michael; Strebel, Räto T.; Perucchini, Daniele; Scheiner, David; Schaer, Gabriel N.; John, Hubert; Reitz, André; Hauri, D.; Schurch, Brigitte

doi:10.1016/s0022-5347(06)00590-8

Cited by 218 publications

(168 citation statements)

References 20 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…The e¡ect of detrusor injections of botulinum toxin in PD to treat severe DO remains to be explored.Whereas this treatment has been shown to be so e¡ective in treating DO of spinal origin [Schurch et al, 2000] or even idiopathic DO [Popat et al, 2005;Schmid et al, 2006], it may well be that the overactive bladder of PD which is of central origin, may not respond.…”

Section: Treatment Of Bladder Symptoms In Pdmentioning

confidence: 99%

Update on the neurology of Parkinson's disease

Fowler

2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

The di¡erential diagnosis of a patient with apparent Parkinson's Disease (PD) and bladder symptoms is considered and the bladder dysfunction of Multiple System Atrophy (MSA) is reviewed. Recent insights into the progression of the neuropathology of PD have enabled thinking about the stage of the disease at which bladder dysfunction is likely to occur and the expected clinical context of the problem. Bladder symptoms of neurological origin are likely in a patient who has had treated motor symptoms for some years and in whom the ongoing neuropathology has progressed beyond involvement of the basal ganglia, so that symptoms due to cortical dysfunction as well as the adverse e¡ects of dopaminergic medication are also confounding factors. Bladder symptoms in a man with lesser neurological disability should be investigated to exclude underlying out£ow obstruction. Possible management options are considered. Neurourol. Urodynam. 26: 103^109, 2007.

show abstract

Section: Treatment Of Bladder Symptoms In Pdmentioning

confidence: 99%

Update on the neurology of Parkinson's disease

Fowler

2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Ancak son y›llarda BoNT daha çok detrüsör afl›r› aktivitesini tedavi etmek için denenmeye bafllanm›flt›r. Tedavi sonras› ifleme s›ras›nda detrüsör bas›nçlar›nda ve istemsiz kas›lmalarda azalma görülmesi BoNT in detrüsörün motor innervasyonu üzerindeki etkisine dair kan›tlar sa¤lam›fl ve hastalar›n s›k›flma hissinde azalma oldu¤unu belirtmesi de afferent mekanizmalar da da etkisi oldu¤unu göstermifltir (11,12) .…”

Section: Botul‹nyum Toks‹n‹ Enjeks‹yonuunclassified

Botulinum toxin and neuromodulation for overactive bladder treatment

Akman¹

2013

J Turk Soc Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…In den 16 open-label Studien [9,[12][13][14][15]17,18,[24][25][26][27][28][29][30][31][32] wurde eine ähnliche Effektivität von BoNT/A zur Behandlung der NNOAB/IDO gefunden wie in den beiden doppelblinden, placebokontrollierten, randomisierten Studien. Insgesamt zeigen die Studien jedoch ein inhomogenes Bild was die Parameter der Auswertung, die Zeitpunkte der Nachkontrolle und die statistische Darstellung der Ergebnisse betrifft, so dass es häufig sehr schwer ist, einzelne Studien überhaupt miteinander zu vergleichen (Tabelle 2).…”

Section: Offene Nicht Kontrollierte Studienunclassified

“…Insgesamt zeigen die Studien jedoch ein inhomogenes Bild was die Parameter der Auswertung, die Zeitpunkte der Nachkontrolle und die statistische Darstellung der Ergebnisse betrifft, so dass es häufig sehr schwer ist, einzelne Studien überhaupt miteinander zu vergleichen (Tabelle 2). So wurde lediglich in 7 von 16 Studien [12][13][14]18,25,28,30] eine genaue Angabe zur Veränderung des IHD gemacht, obwohl dieser das Hauptsymptom der OAB ist [1].…”

Section: Offene Nicht Kontrollierte Studienunclassified

Botulinumtoxin bei nichtneurogenen Blasenfunktionsstörungen

Mehnert

Schurch

2009

Urologe

Self Cite

View full text Add to dashboard Cite

Die nichtneurogene überaktive Harnblase mit oder ohne Detrusorüberaktivität und/oder Inkontinenz ist ein belastendes Symptom für viele Menschen, das bis vor wenigen Jahren nur mit anticholinergen Medikamenten oder operativ behandelt werden konnte. Intradetrusorinjektionen mit Botulinumtoxin Typ A stellen eine minimal-invasive Alternative für Patienten dar, die auf Anticholinergika nicht ansprechen oder diese nicht vertragen. Dieser Übersichtsartikel fasst die relevanten Arbeiten der letzten 6 Jahre zu diesem Thema zusammen und gibt Auskunft über die Wirksamkeit, die Nebenwirkungen, die verwendeten Dosierungen und Injektionstechniken. Insgesamt zeigte sich eine gute initiale Wirksamkeit, die etwa ab dem 4. Tag nach Injektion beginnt und durchschnittlich bis zu 31 Wochen anhalten kann. Es ist allerdings je nach Dosis mit einer Erhöhung der Restharnmengen zu rechnen, die auch die Anwendung von intermittierendem Selbstkatheterismus notwendig machen können. Die Anwendung von Botulinumtoxin in der Harnblase ist noch immer keine offiziell zugelassene Therapie. = Nonneurogenic overactive bladder with or without detrusor overactivity and/or incontinence is a bothersome symptom for many people. Until a few years ago, it could be treated only with anticholinergic drugs or invasive surgery. Intradetrusor injection with botulinum toxin type A is a minimally invasive alternative therapy option for patients who do not respond to or tolerate anticholinergic treatment. This literature overview summarises the relevant articles on this topic over the last 6 years and provides information on the efficacy, adverse events, currently used dosages, and injection techniques. Overall, a favourable initial efficacy has been observed starting around day 4 after injection and can last up to approximately 31 weeks. Depending on the dose, however, elevated postvoid residual volumes should be anticipated and might require clean intermittent self-catheterisation. The use of botulinum toxin in the urinary bladder is still considered off-label. Botulinum toxin in non-neurogenic bladder dysfunctionNon-neurogenic overactive bladder with or without detrusor overactivity and/or incontinence is a bothersome symptom for many people that could be treated only with anticholinergic drugs or invasiv surgery until a few years ago. Intradetrusor injection with botulinum toxin type-A is a minimally invasive alternative therapy option for patients, who do not respond to or tolerate anticholinergic treatment. This literature overview summarises the relevant articles on this topic of the last 6 years and provides information on the efficacy, adverse events, currently used dosages and injection techniques. Overall a favourable initial efficacy could be observed starting around day 4 after injection, which can last approximately up to 31 weeks. Depending on the dose however, elevated post void residual volumes have to be anticipated, which might even require clean intermittend self catheterisation. The use of botulinum toxin in the urinary bladder is stil...

show abstract

Experience With 100 Cases Treated With Botulinum-A Toxin Injections in the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome Refractory to Anticholinergics

Abstract: Our results show that intradetrusor botulinum-A toxin injections may be an efficient and safe treatment option in patients with severe overactive bladder resistant to all conventional treatments.

Cited by 218 publications

References 20 publications

Update on the neurology of Parkinson's disease

Update on the neurology of Parkinson's disease

Botulinum toxin and neuromodulation for overactive bladder treatment

Botulinumtoxin bei nichtneurogenen Blasenfunktionsstörungen

Contact Info

Product

Resources

About